High organic sales growth and stronger margins despite geopolitical headwinds

Getinge Q3 2025

Mattias Perjos, CEO Agneta Palmér, CFO



Key pillars for Getinge's profitable growth journey

Development for strategic KPIs



Improvements should be achieved through balanced leverage² and attractive long-term Return on Invested Capital³




Key takeaways

Q3 2025

- Net sales grew by 9.5% organically and order intake increased by 4.7% organically
- Margins positively impacted by acquisitions, price, mix and productivity
- The financial position remains solid







Key activities and events

Q3 2025

Offering and customers

- Getinge's T-DOC provides the software intelligence in Sweden's first fully automated Central Sterile Supply Department at Malmö University Hospital.
- Getinge Manufacturing Excellence has realized lead time reduction in Life Science for some products in category WIS by more than 20% and COGS by about 10%.
- Partnership with Philips to offer hospitals in CE markets an integrated anesthesia workstation for the operating room.





Sustainability and Quality

- CE Mark reinstated for Getinge's Cardiosave Intra-Aortic Balloon Pump. The reinstatement is subject to certain conditions, which Getinge is committed to fulfilling.
- EU MDR approval of further indications for our V12 balloon expandable covered stents. The approval of three different indicators (BEVAR, FEVAR and IBD) represents a key enabler for growth in the European endovascular market.
- CO2 emissions continue to decrease.







Solid organic Net Sales growth in all Business Areas and regions

Order Intake and Net Sales Bridge Q3 2024 – Q3 2025

Order Intake



Net Sales







Margins increased in the quarter despite headwinds from tariffs and FX

Adjusted Gross Profit and EBITA Bridge Q3 2024 – Q3 2025

Adjusted Gross Profit



Adjusted EBITA







Tariffs having a material impact on adjusted EBITA

Impact from tariffs

Reminder from the Q1 presentation



Impact on adj EBITA in Q3 2025



Impact on adj EBITA YTD 2025


Approx
-218
MSEK




But efforts to mitigate negative impact from tariffs are clearly working

Impact on margin from tariffs and FX

Reminder from the Q2 presentation



Illustrative view on adj EBITA margin excl tariffs and FX in



Restatement: With current tariff levels, Getinge expects to reach the target of >12% average annual growth in adjusted EPS 2024-2028





Getinge has a solid financial position

Improved FCF Y-o-Y and good safety margin on leverage despite significant acquisition

FCF positively impacted by improved operating profit...

... and leverage continues to be well below 2.5x





Free Cash Flow, SEK B

Net debt/Adj EBITDA R12



Outlook 2025

Net sales for 2025 expected to increase by 2-5% organically





Summary



Key takeaways

Summary Q3 2025

- Strong performance in the quarter with solid organic growth
- Improved margins despite tariffs and negative FX
- The financial position remains solid
- Outlook for 2025: organic net sales growth of 2-5%



Q&A



Thank you



Forward looking information

This document contains forward-looking information based on the current expectations of the Getinge's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.





PASSION FOR LIFE